Chinese company offers ‘free toilet use' and lift access as employee benefits
A job advertisement by a Chinese company has been ridiculed online for listing basic workplace necessities such as free toilet use and lift access as employee benefits.The ad, which also promised 'no electricity charges for overtime,' surfaced on April 29 after it was shared by a popular social media account called Workplace Slackers, South China Morning Post reports.While the post refrained from naming the company or specifying the job title, it did mention that the role involved order processing and required attention to detail and good Excel skills.advertisement
The role involved an eight-hour workday, including a one-hour break, with shift options of either 9am to 6pm or 1pm to 10pm. During the probation period, the monthly salary will be 4,000 yuan. Employees would get four days off each month and receive double pay on national holidays.However, it was the unusual list of 'benefits' because of which the job advertisement went viral. Apart from free toilets and lift access, the ad mentioned occasional team-building activities, afternoon tea, and late-night snacks. It also offered a raise of 100 yuan (US$14) per month after completing one year on the job.According to the South China Morning Post report, several users slammed the company, saying: 'These so-called job benefits should be standard? How can they be listed as perks?'The job market in China is challenging enough as workers often deal with long hours, low wages, difficult working conditions, and limited job security. Age discrimination is another concern, as several individuals find it difficult to find jobs after turning 35.advertisementAccording to China's Labour Contract Law, employees are not allowed to work more than eight hours a day or 44 hours a week on average. The law also mandates that employers offer basic benefits, including a pension, medical coverage, and unemployment insurance.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
2 hours ago
- Time of India
Steven Adams signs $39 million 3-year extension with Houston Rockets, says report
New Zealand basketball center Steven Adams has agreed to a three-year, USD $39 million ($65million) contract extension to stay with the Houston Rockets, according to ESPN. The new deal keeps a top center out of free agency after playing a key rotation and leadership role in the franchise's playoff run. The Kiwi NBA star was off contract this season, but according to ESPN, he will remain in Houston after being traded to the Rockets from the Memphis Grizzlies in February 2024. He missed the 2023-24 season due to a knee injury but played an instrumental role during the 2024-25 season as the Rockets bagged the second position in the Western Conference before falling to the Golden State Warriors in the first round. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Play War Thunder now for free War Thunder Play Now Undo Adams, 32, stepped into the world of the NBA in 2013. A three-year deal would see the top center in the league until 2028. According to Basketball Reference, Adams has already earned around US$159m ($264.7m) across his career to date. This new deal would take him over the $300 million mark. In the 2024-25 season, Adams appeared in 58 games, averaging 3.9 points and 5.6 rebounds, as the team ended up in the second position in the West with a 52-30 record. The Rockets went on to lose to a much more experienced Golden State team in the first round of the playoffs. Adams is often seen as a key contributor in the playoffs. Live Events In the playoffs, he averages 22.1 minutes per game with 5.7 points and 6.6 rebounds. His defensive presence and offensive reboundary played a pivotal role in the Rockets' playoff run. Adams has played in 11 NBA seasons, spending his first seven in Oklahoma City.
India Today
3 hours ago
- India Today
5 years since Galwan, how India has fortified border with reforms and roads
Five years ago, on June 15, 2020, India lost 20 soldiers in the Galwan Valley clash with China in Eastern Ladakh - an event that not only redefined India-China ties but also triggered a series of reforms in India's defence posture and strategic planning along the Line of Actual Control (LAC).The Galwan clash, which saw Indian troops retaliate without firearms under existing protocols, also caused significant casualties on the Chinese side and marked a complete breakdown in trust between the two the years since, India has significantly restructured its military preparedness, reinforced border infrastructure, and intensified diplomatic engagements. The Indian armed forces enhanced their presence across the LAC, especially in Eastern Ladakh, with rapid deployment of troops and high-altitude warfare equipment. Emergency procurement provisions were invoked to expedite defence acquisitions, including surveillance systems, UAVs, artillery, and medical equipment for extreme terrain. The Galwan incident became a catalyst for infrastructure expansion. The Union Budget for FY 2025-26 allocated Rs 6.81 lakh crore to the Ministry of Defence, a 9.53% increase from the previous year. Of this, Rs 7,146 crore was set aside for the Border Roads Organisation (BRO), which completed 75 projects worth Rs 2,236 crore in 2024 include roads and bridges in strategic regions like Ladakh, Arunachal Pradesh, Sikkim, and Himachal Pradesh. BRO's earlier achievements included the world's highest motorable road at Umling La (19,024 feet) and ongoing development of the Nyoma Airfield and Shinku La last five years have also seen the LAC's digital landscape transformed. Remote villages in Ladakh, including Galwan and Demchok, were connected to 4G networks under a joint initiative by the Indian Army and Bharti Airtel. This step opened up access to telemedicine, digital education, and government schemes, with the potential to improve tourism and local the diplomatic front, over 30 rounds of talks have taken place since 2020. India and China have conducted 21 rounds of Corps Commander-level discussions and multiple Working Mechanism for Consultation & Coordination (WMCC) meetings. Disengagement has occurred at several friction points: Galwan in July 2020, Pangong Tso in February 2021, PP17A (Gogra-Hot Springs) in August 2021, PP15 in September 2022, and most recently, at Demchok and Depsang in October diplomatic meetings also continued. On June 12, 2025, Foreign Secretary Vikram Misri met Chinese Vice Foreign Minister Sun Weidong in Delhi to discuss bilateral ties, people-centric engagement, and reopening direct air services. Talks included progress on resuming hydrological data sharing and finalising an updated air services agreement. Visa facilitation, media exchanges, and commemorations of 75 years of India-China diplomatic relations were also partial disengagement, India remains cautious. 'Galwan was a turning point,' says Maj Gen Ashok Kumar (Retd), Director General of Centre for Joint Warfare Studies. 'It shattered all trust in Chinese political and military leadership. India's vigilance along the LAC is now permanent.'India's response post-Galwan is widely seen as a comprehensive shift—not only in defence and diplomacy but in redefining the strategic calculus of border management. The clash, now etched in national memory, has ensured that preparedness, infrastructure, and international positioning are not reactive but Watch
Mint
3 hours ago
- Mint
China's Biotech Moment Ignites a 60% Stock Rally That Beats AI
China's biotechnology stocks have shaken off a four-year slump to be among the hottest performers in Asia this year and funds are tipping further gains. The Hang Seng Biotech Index has surged more than 60% since the start of January amid investor enthusiasm over a pair of billion-dollar deals involving foreign firms licensing Chinese drugs. Share gains at two highly anticipated listings of local producers have further burnished the sector's appeal. 'China biotech is no longer just an emerging story — unlike 10 years ago — it is now a disruptive force reshaping global drug innovation,' said Yiqi Liu, senior investment analyst at Exome Asset Management LLC in New York. 'The science is real, the economics are compelling, and the pipeline is starting to deliver.' The surge in China-listed biotech firms is further evidence that the mainland is becoming a center for global innovation. The rally in the sector this year outpaces the 17% gain in China's tech stocks that was driven by the release of DeepSeek's breakthrough artificial-intelligence app in January. A major reason for the share gains were two mega-sized licensing deals. Pfizer Inc. said on May 19 it had agreed to pay a record $1.25 billion to license an experimental cancer drug from China's 3SBio Inc., and also invest $100 million in the firm's shares. Two weeks later, Bristol-Myers Squibb Co. said it would pay Germany's BioNTech SE as much as $11.5 billion to license a cancer drug that BioNTech had itself licensed from China's Biotheus Inc. in 2023. Some of the gains in biotech shares this year have been stratospheric. 3SBio has surged 283%, topping a Bloomberg gauge of global biotech stocks. RemeGen Co., which develops antibody drugs, has climbed more than 270% after saying it was approached by multinational pharmaceutical firms for potential licensing deals. China's growing influence through pharmaceutical mergers and acquisitions and deal-making is also causing investors to take note. In the first quarter alone, the value of such deals involving local players doubled from the year before to $36.9 billion. That amount made up more than half the global total of $67.5 billion. Chinese biotech companies are having 'their own DeepSeek moment,' said Dong Chen, chief Asia strategist at Pictet Wealth Management in Hong Kong. There is more upside from here, he said. Investor interest in biotech — which involves the use living organisms to make medicines and other products — can be seen in the big runup at recent initial public offerings. Shares of Duality Biotherapeutics Inc., which develops cancer treatments, more than doubled on their first day of trading in Hong Kong on April 15. Jiangsu Hengrui Pharmaceuticals Co., the nation's largest drugmaker by market value, saw its stock jump 25% on debut May 23, even after being issued at the top end of the marketed range. Duality has now risen 189% since its IPO, while Jiangsu has gained 31%. Still, some say the rally may be getting stretched. 'Bears, mostly healthcare specialists, plan to take profit at this point, and some investors prefer the healthcare laggers with capability of constant dividend payout and stable revenue growth,' Bank of America Corp. analysts including Ethan Cui in Hong Kong wrote in a research note this month. Some investors also said they viewed the rush of recent licensing deals as a one-off, and they were refusing to grant valuation multiples to the companies, the analysts wrote. While the recent ratcheting up of trade tensions between the US and China has been a negative for many mainland firms, it's also resulted in talent flowing back to China and creating more research-and-development capability, according to Nicholas Chui, a Chinese equity fund manager at Franklin Templeton in Hong Kong. Jefferies is also bullish, saying the increase in US tariffs is unlikely to prove an obstacle to Chinese biotech firms. Many of the Chinese biotech companies already have US partners and are therefore considered as service providers rather than product exporters, said Cui Cui, head of Asia healthcare research at the company in New York. With assistance from Dong Lyu. This article was generated from an automated news agency feed without modifications to text.
